Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $139.39 Consensus PT from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been assigned a consensus rating of “Hold” from the fourteen ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $135.40.

Several analysts have recently weighed in on ZBH shares. Oppenheimer lifted their target price on shares of Zimmer Biomet from $150.00 to $155.00 and gave the company an “outperform” rating in a report on Friday. StockNews.com cut Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. Citigroup lifted their price target on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Evercore ISI increased their price objective on Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 9th.

Zimmer Biomet Stock Up 2.7 %

ZBH opened at $121.66 on Tuesday. Zimmer Biomet has a 52 week low of $102.00 and a 52 week high of $147.50. The business has a 50 day moving average price of $125.30 and a two-hundred day moving average price of $120.02. The company has a quick ratio of 0.78, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. The company has a market cap of $25.00 billion, a PE ratio of 26.33, a P/E/G ratio of 2.17 and a beta of 1.03.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, topping the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The business had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter in the prior year, the business earned $1.89 earnings per share. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. As a group, research analysts anticipate that Zimmer Biomet will post 8.08 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were paid a dividend of $0.24 per share. The ex-dividend date was Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the transaction, the vice president now owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.95% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds have recently modified their holdings of the company. OLD Point Trust & Financial Services N A acquired a new stake in Zimmer Biomet during the fourth quarter worth approximately $26,000. Ables Iannone Moore & Associates Inc. acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth $30,000. Naples Money Management LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter valued at $35,000. Activest Wealth Management increased its stake in Zimmer Biomet by 410.4% in the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 275 shares during the last quarter. Finally, Peoples Bank KS acquired a new stake in Zimmer Biomet in the 3rd quarter worth about $48,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.